Ribupatide injection
KAI-9531 · HRS9531 · Ribupatide · Kailera Therapeutics
Global Phase 3 is underway; U.S. high-dose Phase 2b results are expected in mid-2027.
Selected study results
GEMINI-1 · ChinaMean body-weight changeBody weight decreased 17.7% · 48 weeks · Phase 3
Mean body-weight change · 48 weeks
Study focus: Weight management
GEMINI-1: randomized, double-blind, placebo-controlled Phase 3 trial at 55 sites in China.
Adults with overweight or obesity in China without diabetes · 6 mg weekly vs placebo · Trial N=567 · Primary treatment-policy estimand. Results & methods ↗ · Publication ↗
Gastrointestinal adverse events occurred in 63.1% with 6 mg and 23.1% with placebo, mostly mild to moderate. These China results are separate from the global KaiNETIC program.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: Enrollment complete across KaiNETIC-1, -2 and -3; sponsor expects topline results in mid-2028.
Next: KaiNETIC topline results expected mid-2028.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies4 records
GEMINI-1 · China
Weight management · China567 adults without diabetes in China; ribupatide 2, 4 or 6 mg weekly versus placebo for 48 weeks. Primary treatment-policy results published in JAMA.
KaiNETIC-1
Weight managementGlobal chronic weight-management study in adults with obesity or overweight without type 2 diabetes. Enrollment complete per September 30 sponsor announcement; topline expected mid-2028.
KaiNETIC-2
Weight management with type 2 diabetesGlobal chronic weight-management study in adults with obesity or overweight and type 2 diabetes. Enrollment complete per September 30 sponsor announcement; topline expected mid-2028.
KaiNETIC-3
Comparative weight managementGlobal chronic weight-management study in adults with BMI at least 35 without type 2 diabetes; semaglutide comparator. Enrollment complete per September 30 sponsor announcement; topline expected mid-2028.
Phase 2 studies1 record
U.S. high-dose Phase 2b study
Weight management48-week dose-ranging injectable study; separate from the global Phase 3 KaiNETIC studies.
